Andera Partners Co-Leads €105M Series A for Biopharma Innovator Adcytherix
Andera Partners has co-led a €105 million Series A round for Adcytherix, marking the first investment from its BioDiscovery 7 fund in innovative biopharma solutions.
- On October 16, 2025, Andera Partners co-led a €105 million Series A round for Adcytherix, focusing on developing proprietary antibody drug conjugates.
- This financing round is the inaugural investment from Andera Partners BioDiscovery 7 fund, emphasizing their commitment to biopharmaceutical innovation.
- Additional support in this funding round came from notable investors including Bpifrance and Kurma, highlighting strong confidence in Adcytherixs potential.
Por Qué Es Relevante
This significant investment underscores the growing interest in biopharmaceutical advancements, particularly in antibody drug conjugates, which could lead to groundbreaking treatments and impact global healthcare.